Jason Butler
Stock Analyst at Citizens
(4.64)
# 188
Out of 5,154 analysts
141
Total ratings
50.68%
Success rate
44.19%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Market Outperform | $88 → $96 | $60.41 | +58.91% | 18 | Feb 25, 2026 | |
| IRWD Ironwood Pharmaceuticals | Upgrades: Market Outperform | $8 | $3.50 | +128.57% | 2 | Jan 5, 2026 | |
| NSRX Nasus Pharma | Initiates: Market Outperform | $19 | $4.86 | +290.95% | 1 | Dec 18, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $114 → $131 | $109.33 | +19.82% | 5 | Dec 16, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $11 → $19 | $9.59 | +98.12% | 12 | Dec 1, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $91 → $92 | $67.37 | +36.56% | 14 | Nov 4, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Market Outperform | $9 → $12 | $4.22 | +184.36% | 8 | Oct 9, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $30.24 | -7.41% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $22.16 | +66.97% | 15 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $15.93 | +144.82% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.32 | +80.72% | 11 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $115 → $100 | $29.28 | +241.53% | 1 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $42 → $38 | $28.34 | +34.09% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $8.98 | +100.45% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $2.72 | +47.06% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $717.79 | -2.34% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $3.11 | +189.39% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $6.46 | +194.12% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.01 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $8.67 | +484,329.07% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $13.54 | +756.72% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $4.53 | +98.68% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.91 | - | 1 | Dec 2, 2020 |
Cytokinetics
Feb 25, 2026
Maintains: Market Outperform
Price Target: $88 → $96
Current: $60.41
Upside: +58.91%
Ironwood Pharmaceuticals
Jan 5, 2026
Upgrades: Market Outperform
Price Target: $8
Current: $3.50
Upside: +128.57%
Nasus Pharma
Dec 18, 2025
Initiates: Market Outperform
Price Target: $19
Current: $4.86
Upside: +290.95%
ABIVAX Société Anonyme
Dec 16, 2025
Maintains: Market Outperform
Price Target: $114 → $131
Current: $109.33
Upside: +19.82%
Prothena Corporation
Dec 1, 2025
Maintains: Market Outperform
Price Target: $11 → $19
Current: $9.59
Upside: +98.12%
Halozyme Therapeutics
Nov 4, 2025
Maintains: Market Outperform
Price Target: $91 → $92
Current: $67.37
Upside: +36.56%
Aquestive Therapeutics
Oct 9, 2025
Maintains: Market Outperform
Price Target: $9 → $12
Current: $4.22
Upside: +184.36%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $30.24
Upside: -7.41%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $22.16
Upside: +66.97%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $15.93
Upside: +144.82%
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $3.32
Upside: +80.72%
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $29.28
Upside: +241.53%
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $28.34
Upside: +34.09%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $8.98
Upside: +100.45%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $2.72
Upside: +47.06%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $717.79
Upside: -2.34%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $3.11
Upside: +189.39%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $6.46
Upside: +194.12%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $6.01
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $8.67
Upside: +484,329.07%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $13.54
Upside: +756.72%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $4.53
Upside: +98.68%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.91
Upside: -